Co-Author
This page shows the publications co-authored by Yanan Kuang and Cloud Paweletz.
Connection Strength
1.766
-
Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR. Methods Mol Biol. 2018; 1768:193-207.
Score: 0.742
-
Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer. 2018; 4:22.
Score: 0.193
-
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. Clin Cancer Res. 2016 Feb 15; 22(4):915-22.
Score: 0.159
-
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance. Mol Cancer Ther. 2022 02; 21(2):322-335.
Score: 0.061
-
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer. Sci Transl Med. 2021 Sep; 13(609):eabb3738.
Score: 0.060
-
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell. 2020 12 14; 38(6):872-890.e6.
Score: 0.057
-
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nat Commun. 2020 05 11; 11(1):2350.
Score: 0.055
-
Circulating Donor-derived Cell-free DNA as a Biomarker in Vascularized Composite Allotransplantation? Transplantation. 2020 03; 104(3):e79-e80.
Score: 0.054
-
Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Clin Cancer Res. 2019 12 15; 25(24):7287-7293.
Score: 0.052
-
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med. 2018 08; 24(8):1143-1150.
Score: 0.048
-
False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clin Cancer Res. 2018 09 15; 24(18):4437-4443.
Score: 0.047
-
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. Proc Natl Acad Sci U S A. 2017 05 30; 114(22):E4482-E4491.
Score: 0.044
-
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discov. 2016 12; 6(12):1334-1341.
Score: 0.042
-
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet. 2015 Oct; 47(10):1212-9.
Score: 0.039
-
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Cancer Res. 2015 Oct 15; 75(20):4372-83.
Score: 0.039
-
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015 Jun; 21(6):560-2.
Score: 0.039
-
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014 Mar 15; 20(6):1698-1705.
Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.